131 related articles for article (PubMed ID: 28264644)
21. Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.
Proschmann R; Baldow C; Rothe T; Suttorp M; Thiede C; Tauer JT; Müller MC; Hochhaus A; Roeder I; Glauche I
Haematologica; 2017 Feb; 102(2):e39-e42. PubMed ID: 27856510
[No Abstract] [Full Text] [Related]
22. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
23. Chronic myelogenous leukemia stem cells: What's new?
Copland M
Curr Hematol Malig Rep; 2009 Apr; 4(2):66-73. PubMed ID: 20425417
[TBL] [Abstract][Full Text] [Related]
24. Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose.
Bono S; Dello Sbarba P; Lulli M
Stem Cell Res; 2018 Apr; 28():33-38. PubMed ID: 29414416
[TBL] [Abstract][Full Text] [Related]
25. Imatinib resistance in chronic myeloid leukemia due to a rare mutation.
Balasubramanian P; Chopra A; Verma D; Singh IK; Kumar A; Sharma A; Kumar R
Leuk Lymphoma; 2017 Jul; 58(7):1750-1752. PubMed ID: 27868464
[No Abstract] [Full Text] [Related]
26. Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells.
Than H; Pomicter AD; Yan D; Beaver LP; Eiring AM; Heaton WL; Senina A; Clair PM; Shacham S; Mason CC; Hare TO; Deininger MW
Leukemia; 2020 Jun; 34(6):1679-1683. PubMed ID: 31980730
[No Abstract] [Full Text] [Related]
27. LSK derived LSK- cells have a high apoptotic rate related to survival regulation of hematopoietic and leukemic stem cells.
Peng C; Chen Y; Shan Y; Zhang H; Guo Z; Li D; Li S
PLoS One; 2012; 7(6):e38614. PubMed ID: 22675576
[TBL] [Abstract][Full Text] [Related]
28. Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes.
Anusha ; Dalal H; Subramanian S; V P S; Gowda DA; H K; Damodar S; Vyas N
Cell Death Dis; 2021 Mar; 12(3):259. PubMed ID: 33707419
[TBL] [Abstract][Full Text] [Related]
29. Chronic myeloid leukemia: reaching for the cure.
Nencioni A; Cea M; Montecucco F; Gobbi M; Patrone F
Curr Cancer Drug Targets; 2013 Sep; 13(7):709-10. PubMed ID: 23957630
[No Abstract] [Full Text] [Related]
30. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
[TBL] [Abstract][Full Text] [Related]
31. Role of SIRT1 in the growth and regulation of normal hematopoietic and leukemia stem cells.
Li L; Bhatia R
Curr Opin Hematol; 2015 Jul; 22(4):324-9. PubMed ID: 26049753
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations.
Giuntoli S; Rovida E; Barbetti V; Cipolleschi MG; Olivotto M; Dello Sbarba P
Leukemia; 2006 Jul; 20(7):1291-3. PubMed ID: 16710305
[No Abstract] [Full Text] [Related]
33. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
34. Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.
Sazawal S; Chikkara S; Singh K; Chaubey R; Chandra D; Mishra P; Mahapatra M; Seth T; Saxena R
Ann Diagn Pathol; 2017 Apr; 27():24-27. PubMed ID: 28325357
[TBL] [Abstract][Full Text] [Related]
35. Novel strategies to eradicate resistant cells in chronic myeloid leukemia.
Schoepf AM; Gust R
Future Med Chem; 2020 Dec; 12(23):2089-2092. PubMed ID: 33228384
[No Abstract] [Full Text] [Related]
36. Mutations in ABL kinase domain are associated with inferior progression-free survival.
Sharma P; Mohanty S; Kochupillai V; Kumar L
Leuk Lymphoma; 2010 Jun; 51(6):1072-8. PubMed ID: 20367437
[TBL] [Abstract][Full Text] [Related]
37. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS
Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192
[TBL] [Abstract][Full Text] [Related]
38. Spred1 deficit promotes treatment resistance and transformation of chronic phase CML.
Qiao J; Liang C; Zhao D; Nguyen LXT; Chen F; Suo S; Hoang DH; Pellicano F; Rodriguez IR; Elhajmoussa Y; Ghoda L; Yoshimura A; Stein AS; Ali H; Koller P; Perrotti D; Copland M; Han A; Zhang BA; Marcucci G
Leukemia; 2022 Feb; 36(2):492-506. PubMed ID: 34564700
[TBL] [Abstract][Full Text] [Related]
39. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
40. BCR-ABL insufficiency for the transformation of human stem cells into CML.
Matioli GT
Med Hypotheses; 2002 Nov; 59(5):588-9. PubMed ID: 12376083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
